BLA 761067 · Sun Pharma Global
Ilumya
Tildrakizumab-Asmn · Injection · Interleukin-23 Antagonist
NovelLast checked: Nov 20, 2026Latest source record: Oct 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Mar 20, 2018
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
30
12 Phase 3, 5 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Tildrakizumab" as an intervention, any sponsor and status, largest first.
Sun Pharmaceutical Industries LimitedIndustry
NCT01729754 · 1,090 participants · Start Feb 5, 2013 · Primary completion Sep 28, 2015
Drug: Tildrakizumab 200 mg; Tildrakizumab 100 mg and 3 more · For: Plaque Psoriasis
- A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)Pivotal-lookingCompleted
Sun Pharmaceutical Industries LimitedIndustry
NCT01722331 · 772 participants · Start Dec 6, 2012 · Primary completion Oct 28, 2015
Drug: Tildrakizumab 200 mg; Tildrakizumab 100 mg and 1 more · For: Plaque Psoriasis
- Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic ArthritisPivotal-lookingActive, not recruiting
Sun Pharmaceutical Industries LimitedIndustry
NCT04991116 · 529 participants · Start Jun 30, 2022 · Primary completion Dec 2028
Drug: TILD sub-cutaneous (SC) injection · For: Psoriatic Arthritis
Sites: Dothan, Alabama; Gilbert, Arizona; Mesa, Arizona · 99 sites in all
- Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)Pivotal-lookingCompleted
Sun Pharmaceutical Industries LimitedIndustry
NCT04314544 · 508 participants · Start Jul 1, 2020 · Primary completion Mar 26, 2025
Drug: TILD; matching placebo injections · For: Active Psoriatic Arthritis
Sites: Dothan, Alabama; Gilbert, Arizona; Glendale, Arizona · 97 sites in all
- Efficacy and Safety Study of SUNPG1623Pivotal-lookingCompleted
Sun Pharmaceutical Industries LimitedIndustry
NCT02980692 · 391 participants · Start Apr 19, 2017 · Primary completion Mar 1, 2019
Drug: SUNPG1623 I; SUNPG1623 II and 3 more · For: Active Psoriatic Arthritis
Sites: Middleburg Heights, Ohio
- A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01225731 · 355 participants · Start Oct 25, 2010 · Primary completion Nov 4, 2011
Drug: tildrakizumab; Placebo · For: Psoriasis
- Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)Pivotal-lookingActive, not recruiting
Sun Pharmaceutical Industries LimitedIndustry
NCT04314531 · 296 participants · Start Jul 1, 2020 · Primary completion Jun 4, 2025
Drug: TILD; matching placebo injections · For: Active Psoriatic Arthritis
Sites: Covina, California; Miami Beach, Florida; New Port Richey, Florida · 49 sites in all
- Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.Pivotal-lookingCompleted
Sun Pharmaceutical Industries LimitedIndustry
NCT03552276 · 281 participants · Start Jul 11, 2018 · Primary completion Sep 18, 2023
Drug: SUNPG18_07 I (Tildrakizumab 200 mg); SUNPG18_07 II (Tildrakizumab 100 mg) · For: Psoriatic Arthritis
Sites: Glendale, Arizona; Phoenix, Arizona; Denver, Colorado · 66 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ilumya (Tildrakizumab-Asmn)
2024 spending
$34.3M
Beneficiaries
696
2,020 claims
Per beneficiary
$49,213
$16,806.74 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $13,660,369 |
| 2021 | $18,490,502 |
| 2022 | $25,027,537 |
| 2023 | $31,759,015 |
| 2024 | $34,252,143 |
Part B: Ilumya (Tildrakizumab-Asmn) · HCPCS J3245
2024 spending
$413M
Beneficiaries
9,049
30,861 claims
Per beneficiary
$45,684
2024 ASP limit $133.54 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $66,825,098 |
| 2021 | $144,583,756 |
| 2022 | $251,905,420 |
| 2023 | $344,295,530 |
| 2024 | $413,395,382 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A, Smolen JS, Ferreira RJO, et al. · Ann Rheum Dis 2024 · Systematic Review
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Garcia-Doval I, et al. · Cochrane Database Syst Rev 2022 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Guelimi R, et al. · Cochrane Database Syst Rev 2025 · Comparative Study, Network Meta-Analysis
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Guelimi R, et al. · Cochrane Database Syst Rev 2023 · Review, Research Support, Non-U.S. Gov't
- Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis.
Thomas SE, Barenbrug L, Hannink G, et al. · Drugs 2024 · Systematic Review, Meta-Analysis
- Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence.
Sun X, Cui Z, Wang Q, et al. · Autoimmun Rev 2024 · Review, Meta-Analysis
Sponsor: Sun Pharma Global
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.